II. Indications
- Antiinflammatory and Immunosuppressant
III. Mechanism
- See Systemic Corticosteroid
- Triamcinolone is an intermediate duration Glucocorticoid
- Intermediate Glucocorticoid potency
- No mineralcorticoid activity
IV. Medications
- Non-Systemic Use (common)
- See Intra-articular Corticosteroid
- Topical Corticosteroid (Triamcinolone Acetonide, Kenalog)
- Intranasal Inhaler (Intranasal Triamcinolone)
- Inhaled Corticosteroid (Inhaled Triamcinolone, Azmacort)
- Azmacort was discontinued in the U.S. in 2016 with the CFC ban
- Systemic (rare systemic use in U.S)
- Triamcinolone (Aristocort, Kenalog)
V. Dosing: Adult
-
General
- Systemic doses are listed for historical purposes (but has rare if any systemic use in the U.S.)
- In contrast, Triamcinolone is among the most commonly prescribed topical and intraarticular Corticosteroids
- Triamcinolone Oral: 4 to 48 mg orally daily
- Triamcinolone IM: 2.5 to 60 mg IM daily
VI. Adverse Effects
VII. Safety
- See Systemic Corticosteroid
- In pregnancy, use only if benefits outweigh risks to fetus
- Avoid in Lactation
VIII. Pharmacokinetics
- Intermediate Glucocorticoid potency
- Intermediate anti-inflammatory potency
- No Mineralocorticoid Activity
- Medium Half-Life
IX. Resources
- Triamcinolone Injection Solution, including Intra-articular Injection use (DailyMed)
X. References
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
- Swadron and Hope in Herbert (2018) EM:Rap 18(9):16-8
- Dvorin (2020) Am Fam Physician 101(2): 89-94 [PubMed]
- Lane (1998) Endocrinol Metab Clin North Am 27:465-83 [PubMed]